FDA recalculation [🇷 for BE/BA]

posted by ElMaestro  – Denmark, 2013-03-20 12:41 (4414 d 23:13 ago) – Posting: # 10245
Views: 12,115

Hi Jérôme,

❝ This question is very interesting in the path of submiting an ANDA to the FDA, because it could put less pressure on software validation for this project?


WHile it is true that FDA routinely recalculate trial outcomes I don't think this in itself relaxes any validation requirements.

Also note that for some re-calculations, if done in SAS, it may not be possible to verify exactly the results from R. The best case I can think of is mixed models with imbalance where the SAS Satterthwaite option for denominator DF's cannot be reproduced in R. There is simply no option for that at present if I remember correctly.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
26 visitors (0 registered, 26 guests [including 11 identified bots]).
Forum time: 12:54 CEST (Europe/Vienna)

The combination of some data and an aching desire
for an answer does not ensure that a reasonable answer
can be extracted from a given body of data.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5